REGN - FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

2024-06-06 12:38:52 ET

Summary

• FibroGen, Inc. top-line data from the phase 2/3 PanCAN Precision Promise study, using pamrevlumab for the treatment of patients with metastatic pancreatic cancer, expected mid-2024.
• Topline data from the phase 3 LAPIS study, using pamrevlumab for the treatment of patients with locally advanced unresectable pancreatic cancer, expected Q3 of 2024.
• Initiation of phase 2 monotherapy dose optimization study of FG-3246 for the treatment of patients with metastatic castration-resistant prostate cancer, expected 2nd half of 2024.
• The global prostate cancer market size is expected to reach $27.51 billion by 2032.
• FG-3175 is an anti-CCR8 inhibitor drug and FG-3165 is an anti-Gal-9 inhibitor; Both drugs are being developed both alone as a monotherapy or as part of a combination with Libtayo for the treatment of patients with solid tumors.

FibroGen, Inc. ( FGEN ) has shifted its focus into developing drug to treat patients with cancer. Thus, it has been able to in-license a few oncology drugs in its pipeline, which are FG-3165 and FG-3175 for the treatment of patients with solid tumors. Each of these drugs has a unique mechanism of action [MOA] and might ultimately pay off. I believe that these programs have a good chance at being moved forward in the clinic, especially since a small collaboration agreement has been made with Regeneron Pharmaceuticals ( REGN ) to advance them. This would be the fact that this big pharma will provide Libtayo [PD-L1 inhibitor] to be used in combination with these two drugs in separate phase 1 studies....

For further details see: